Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00138723 | Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome | PHASE3 | COMPLETED | - | — | — | Oct 1, 2003 | Feb 1, 2005 | Apr 10, 2008 | - | — |
| NCT00220389 | Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase | PHASE2 | COMPLETED | - | — | — | Jun 1, 2003 | Jun 1, 2007 | Oct 16, 2008 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| SPM 907 | DRUG | - |
Inclusion Criteria: * Overactive bladder syndrome Exclusion Criteria: * Less than 8 micturitions in 24 hours